Welcome to our dedicated page for Senti Bioscience news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Bioscience stock.
Senti Biosciences, Inc. (Senti Bio) (NASDAQ: SNTI) is a clinical-stage biotechnology company developing cell and gene therapies that incorporate engineered Gene Circuits. This news page aggregates company announcements, scientific updates, and corporate disclosures so readers can follow how Senti Bio advances its Gene Circuit platform and clinical programs over time.
A major focus of Senti Bio’s news flow is SENTI-202, its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy product candidate. Company releases describe ongoing Phase 1 clinical evaluation of SENTI-202 in adults with relapsed or refractory CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndrome. Updates have highlighted clinical and pharmacodynamic data, presentations at the American Society of Hematology (ASH) Annual Meeting, and FDA designations such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
Visitors can also expect news on Senti Bio’s participation in investor and scientific conferences, quarterly financial result announcements, and communications about its broader Gene Circuit platform. These items provide context on how the company positions its synthetic biology approach, preclinical work in NK and T cells, and efforts to explore Gene Circuits in other modalities and disease areas through partnerships.
For investors and observers tracking SNTI, this page offers a centralized view of press releases and related information, from clinical data readouts and regulatory milestones to corporate presentations. Checking this feed periodically can help users understand the evolution of Senti Bio’s pipeline and its activities within the cell and gene therapy landscape.
Chardan, a global investment bank, has launched its Chardan Equity Facility (ChEF), a new financing solution for public companies. The ChEF allows firms to raise equity periodically, bypassing traditional follow-on offerings. Senti Biosciences (SNTI) has secured a $50 million ChEF, while Dragonfly Energy (CNTQ) has announced a $150 million agreement. Chardan has raised over $30 billion for companies since its inception, including $10 billion for healthcare sectors, positioning itself as a vital partner for capital access in a challenging market.
Senti Biosciences (Nasdaq: SNTI) announced on August 19, 2022, that its compensation committee granted stock options to 35 new employees, totaling 421,659 shares at an exercise price of $1.99 each. This initiative is part of the Company's 2022 Inducement Equity Plan, adopted on August 5, 2022, to attract and retain talent. Senti Bio is focused on innovative cell and gene therapies using a proprietary gene circuit platform, particularly targeting oncology with several programs in development, including treatments for acute myeloid leukemia and hepatocellular carcinoma.
Senti Biosciences, Inc. (SNTI) reported a significant milestone with the selection of a lead development candidate from its SENTI-202 program, targeting acute myeloid leukemia (AML), with an IND filing expected in 2023. As of June 30, 2022, the company holds $139.8 million in cash, sufficient to support operations into 2024. However, R&D expenses increased to $9.2 million, and G&A expenses surged to $13.9 million, contributing to a net loss of $11.6 million for the second quarter, compared to $5.2 million and $4.6 million for the same quarter in 2021, respectively.